For new holders, Sareum is due to update shareholders with its final results sometime in the next couple of weeks. Typically they also provide a research update so we will get updates on our other drug targets FLT3+Aurora and TYK2. Given the massive improvement in cashflow and funding and the prospect of multi million pound milestones in the next year, the news is likely to be positive or at the very least optimistic in terms of being able to progress the programmes. DYOR. S
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.